A new patent licencing deal between Cornell and LNC Therapeutics will help the French biotech become the ‘must have’ partner for research and product development relating to the Christensenella strain, says the company’s CEO.
In the same category
LNC Therapeutics selected by BNP Paribas for its innovative approach to beat obesity
Nov 12, 2019more +
Avec plus de 140 millions d’euros levés, les startups ne ratent pas leur rentrée
Sep 6, 2019more +
LNC Therapeutics raises €6.2 million for the clinical development of new generation gut microbiome...
Sep 5, 2019more +